I. Introduction
Skeletal muscle constitutes up to 50% of total body mass, making it the largest organ in the body. By sheer volume, skeletal muscle metabolism affects the metabolic budget of the whole organism. Indeed, skeletal muscle plays an important role in the regulation of electrolytes such as potassium (Clausen, 1986) and calcium (Levy, 1999) , nutrients such as glucose (Sinacore and Gulve, 1993) , and pH (Juel, 1996) ; in addition, it provides the largest reserve of protein (Rennie et al., 2004) . The metabolic requirements of skeletal muscle are also highly variable-the working contracting muscle is a high consumer of ATP. Skeletal muscle metabolism is also under hormonal control. In the basal (fasting and resting) condition, approximately 80% of blood glucose is metabolized in an insulin-independent manner by the brain, gut, and red blood cells, whereas insulin-sensitive tissues (skeletal muscle and fat) require only small quantities. However, after insulin stimulation, skeletal muscle accounts for 75% of glucose utilization (DeFronzo et al., 1981; Baron et al., 1988; DeFronzo, 1988) . Skeletal muscle is also a primary site of insulin resistance in the context of metabolic disease, in particular, type 2 diabetes and obesity (DeFronzo, 1988; Bouzakri et al., 2005) .
Skeletal muscle is a uniquely plastic tissue and adapts in response to both use and disuse. In response to an increased work load (for example, high-resistance strength training), the muscle used will increase in both size and strength (Hawley and Zierath, 2004; Hawley and Holloszy, 2009 ). In contrast, muscle disuse (such as injury-induced immobilization or bed rest) results in muscle weakness and atrophy (Harridge, 2007) . These responses are localized to the muscle performing the work (or the muscle that has been immobilized), highlighting the idea that local signals within the muscle are likely to be important for this regulation. In addition, systemic factors, including nutritional status and hormones, affect muscle size (Harridge, 2007; Rennie, 2007) . Exercise training also leads to changes in the metabolic phenotype of the muscle. In response to endurance exercise, the number of mitochondria in muscle increases (Holloszy and Booth, 1976; Holloszy and Coyle, 1984) , resulting in an increased capacity of the muscle to sustain aerobic metabolism. In parallel with the increased number of mitochondria, exercise training also leads to increased expression of the insulin-sensitive glucose transporter, GLUT4. Trained muscle derives more of the energy required from fat and less from carbohydrate compared with untrained muscle during submaximal work (work performed below the maximal oxygen utilization capacity). A detailed understanding of the molecular regulation of skeletal muscle metabolism may reveal novel therapeutic targets in the treatment of metabolic disorders. The purpose of this review is to highlight the role that the nuclear receptor PPAR␦ plays in skeletal muscle.
II. Peroxisome Proliferator-Activated Receptor Family
PPARs 1 are ligand-dependent nuclear receptors that belong to the superfamily of nuclear transcription factors. These transcription factors share structural and functional similarities; to date, the superfamily consists of 48 members in humans and 49 in mice (Bookout et al., 2006) . PPAR␦, also known as PPAR␤ or NR1C2, is one of three PPAR isotypes that together constitute group C in subfamily 1 of the superfamily of nuclear receptors (Nuclear Receptors Nomenclature Committee, 1999) . The other two members are PPAR␣ or NR1C1 and PPAR␥ or NR1C3. The PPARs share a high degree of functional and structural similarities, but they are encoded by distinct single-copy genes located on different chromosomes. The human PPARD is located at chromosomal region 6p21.2-p21.1 and consists of nine exons (Skogs-1 Abbreviations: AMPK, AMP-activated protein kinase; bezafibrate, 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; BMI, body mass index; clofibrate, ethyl 2-(4-chlorophenoxy)-2-methylpropanoate; FABP, fatty acid-binding protein; fenofibrate, propan-2-yl 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate; gemfibrozil, 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid; GW0742, 4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethylsulfanyl]-2-methyl-phenoxy}-acetic acid; GW501516, 2- [2-methyl-4-([4-methyl-2-[4-(trifluoromethyl) phenyl)-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid; GW610742X, 3-(4-(3-(4-chloro-2-phenoxyphenoxy)butoxy)-2-ethylphenyl)propionic acid; GWAS, genome-wide association studies; HDL, high-density lipoprotein; L-165041, [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy) propoxy] phenoxy]acetic acid; LBD, ligand-binding domain; MAFbx, muscle atrophy F-box; MBX-8025, {2-methyl-4-[5-methyl-2-(4-trifluoromethyl-phenyl)-2H-[1,2,3]triazol-4-ylmethylsulfanyl]-phenoxy}-acetic acid; MHC, myosin heavy chain; MuRF1, muscle ring finger 1; PDC, pyruvate dehydrogenase complex; PDK, pyruvate dehydrogenase kinase; PGC1␣, PPAR␥ coactivator 1␣; PPAR, peroxisome proliferator-activated receptors; PPRE, peroxisomal proliferator response element; RA, retinoic acid; RXR, retinoid X receptor; SMRT, silencing mediator for retinoic acid and thyroid hormone receptor; SNP, single-nucleotide polymorphism. 374 EHRENBORG AND KROOK berg et al., 2000) , whereas the human PPARA comprises eight exons and is localized at chromosomal region 22q12-q13.1 (Sher et al., 1993; Auboeuf et al., 1997) . The human PPARG has nine exons and is located on chromosome 3p25 . PPAR␥ is the only PPAR that has two distinct full-length translated isoforms . However, several splice variants, including truncated dominant-negative isoforms, have been detected for the three PPARs, the physiological roles of these splice variants need to be further elucidated Palmer et al., 1998; Gervois et al., 1999; Chew et al., 2003; Sabatino et al., 2005; Kim et al., 2006; Lundell et al., 2007) .
A. Tissue Distribution
PPAR␦ is ubiquitously expressed and acts as an important nutritional metabolic sensor and regulator (Barish et al., 2006) . Mice lacking PPAR␦ from genetic ablation have a number of developmental abnormalities. These include placental defects resulting in fewer births than would be expected by mendelian ratio, decreased adipose mass, defective myelination, and altered inflammatory responses (Peters et al., 2000; Tan et al., 2001; Barak et al., 2002) . PPAR␦ has also been demonstrated to be involved in many different biological activities such as lipid and lipoprotein metabolism (Leibowitz et al., 2000; Oliver et al., 2001; Sprecher et al., 2007; Risérus et al., 2008) , skeletal muscle lipid oxidation , inflammation (Tan et al., 2001) , neuronal differentiation (Saluja et al., 2001; Cimini et al., 2003) , mitochondrial respiration Wang et al., 2004) , thermogenesis (Guardiola-Diaz et al., 1999) , determination of skeletal muscle fiber type , keratinocyte differentiation, and wound healing (Tan et al., 2004) . PPAR␣ is mainly expressed in the liver, kidney, heart, and skeletal muscle, where high amounts of fatty acids are metabolized (Abbott, 2009) . PPAR␥ is primarily expressed in adipose tissue promoting adipogenesis and lipid storage, but it is also expressed in the intestine and macrophages (Tontonoz et al., 1994; Lehrke and Lazar, 2005; Abbott, 2009) .
In this review, we limit our scope to PPAR␦-mediated effects in skeletal muscle. In skeletal muscle, PPAR␦ has a higher expression than PPAR␣, PPAR␥ expression being very low (Braissant et al., 1996; Muoio et al., 2002; de Lange et al., 2004) . PPAR␦ also shows a higher expression in oxidative type I muscle fibers compared with glycolytic type II muscle fibers .
B. Peroxisome Proliferator-Activated Receptor Structure and Function
PPARs are predominantly nuclear and regulate transcription by heterodimerizing with the retinoid X receptor (RXR) as shown in Fig. 1 . The receptor complex binds to a peroxisomal proliferator response element (PPRE) located in the regulatory region of a gene and binds to DNA in the absence of ligands (Feige et al., 2005) . The heterodimer is permissive because it can activate transcription in response to only one ligand binding to its specific receptor (i.e., either 9-cis-retinoic acid or a PPAR ligand), but activation by both ligands results in an enhanced induction of gene expression (Kliewer et al., 1992) . The PPRE consists of two direct repeats of the consensus sequence AGGTCA separated by a single nucleotide, which constitutes a DR-1 motif (Kliewer et al., 1992) . Functional PPREs are typically located in the promoter or other regulatory regions of target genes, but it has been reported that PPREs can be located in the FIG. 1. PPAR␦ structure and function. PPAR␦ forms a heterodimer with the RXR and regulates the transcription of genes harboring a PPAR response element. Effects are further modified by specific interactions with cofactors. FABPs may bind and deliver ligands to PPAR␦. A number of possible ligands are depicted, including free fatty acids (FFA), synthetic ligands, and the RXR ligand RA.
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5Ј-transcribed region of specific target genes (Kim and Ahn, 2004) . PPAR binds 5Ј of RXR on the DR-1 motif and the 5Ј-flanking sequence conveys the selectivity of binding between different PPAR isotypes (Juge-Aubry et al., 1997) . Functional PPREs have been found in regulatory regions of genes involved in lipid and glucose homeostasis, inflammation, wound healing, cell proliferation, and differentiation.
The PPAR receptors have four functional domains: A/B, C, D, and E/F (Fig. 2) . The N-terminal A/B domain contains a ligand-independent activation function. This region is not well conserved between the PPAR isotypes. The C domain comprises the DNA binding region, which is highly conserved among the PPARs, and it consists of two zinc-finger-like structures with ␣-helical DNA binding motifs. The D domain includes the hinge region, which is important regarding interaction with cofactors and preservation of the functional structure of the nuclear receptor (Dowell et al., 1997; Miyamoto et al., 2001; Tomaru et al., 2006) . The well-conserved E/F domain consists of the ligand-binding domain (LBD) including the ligand-dependent activation function (AF-2). This region is important for RXR heterodimerization and interaction with coactivators (Nolte et al., 1998; Schulman et al., 1998) . The LBD is composed of 13 ␣-helices and a small four-stranded ␤-sheet forming a very large Y-shaped cavity that is mainly hydrophobic. The cavity of the PPARs is larger than those found in other nuclear receptors, and the entrance of the binding pocket is very flexible, which might explain the ability to bind a range of endogenous and synthetic lipophilic ligands (Nolte et al., 1998; Uppenberg et al., 1998; Xu et al., 1999; Cronet et al., 2001) . Hydrogen bonds between the AF-2 helix and carboxylate groups of endogenous or synthetic ligands are formed whereby the AF-2 helix is folded against the LBD and stabilized, thus enabling binding of coactivator proteins. This conformational change results in release of corepressor proteins that inhibit transcriptional activation (Dowell et al., 1999) .
C. Ligands
Ligands that activate PPARs are all long-chain fatty acids or their derivatives, as well as specific synthetic compounds (Xu et al., 1999; Gervois et al., 2007) . Endogenous substances that can activate PPAR include eicosanoids, leukotrienes, and prostaglandins, but the vitamin A metabolite retinoic acid has also been shown to be a ligand for PPAR␦ (Yu et al., 1995; Schug et al., 2007) . Other endogenous substances that are able to act as PPAR ligands include 8(S)-hydroxyeicosatetraenoic acid and leukotriene B4, whereas 9-hydroxy-10,12-octadecadienoic acid, 13-hydroxy-9,11-octadecadienoic acid, and 15⌬-deoxy-12,14-prostaglandin J 2 activate PPAR␥ (Forman et al., 1995; Kliewer et al., 1995; Devchand et al., 1996; Kliewer et al., 1997; Nagy et al., 1998; Lin et al., 1999) . Whether any of these metabolites is a physiologically relevant PPAR activator in vivo is still not clear.
Synthetic ligands with high specificity for each of the three PPAR isotypes have been developed. Different fibrate compounds such as gemfibrozil, bezafibrate, clofibrate, and fenofibrate are PPAR␣-specific agonists. Fibrates primarily lower the plasma triglyceride concentrations and are used to treat dyslipidemia and cardiovascular disease . Thiazolidinediones are potent and specific PPAR␥ ligands that are used as antidiabetic drugs. The thiazolidinediones delay the onset of type 2 diabetes because of their ability to reduce insulin resistance and ectopic fat accumulation Mayerson et al., 2002; Gerstein et al., 2006) . Regarding PPAR␦-specific agents, no compounds are in clinical use, but two studies in humans have recently been published (Sprecher et al., 2007; Risérus et al., 2008) and are discussed in section IV.A.
PPAR selectivity for different endogenous ligands is determined by several factors. Comparing the the threedimensional structures of the LBD reveals that PPAR␦ has the smallest cavity of the PPAR isotypes. Ligand specificity is determined by the shape complementarity between the cavity and the ligand (Xu et al., 2001) . Thus, a difference of a single amino acid in the PPARs has a remarkable impact on ligand selectivity. Because PPARs are bound to DNA, they need to have their ligands delivered to the nucleus. These transport mechanisms are poorly understood, but it has been shown that fatty acid-binding proteins (FABPs) can transport the ligands to specific PPARs (Fig. 1) . The unliganded FABPs are cytosolic, but upon binding they are transferred to the nucleus and associated with a specific PPAR. FABP5 transfers ligands to PPAR␦, whereas FABP3 and FABP4 shuttle them to PPAR␣ and PPAR␥, respectively (Tan et al., 2002; Schug et al., 2007) . Although the FABPs bind various lipid metabolites with similar affinities, only a few specific ligands induce their nuclear localization depending on whether they can activate a specific PPAR (Gillilan et al., 2007) . The importance of intracellular lipid binding proteins has been shown by studies of retinoic acid (RA). RA activates not only the RA receptor, which cooperates with cellular retinoic acid-binding protein II, but also can activate PPAR␦, which cooperates with FABP5. In cells that express a high FABP5/cellular retinoic acid-binding protein II ratio, RA preferentially activates PPAR␦ despite similar RA receptor and PPAR␦ expression levels, and the much lower affinity of the latter (Schug et al., 2007) .
D. Cofactors
The PPARs require cofactors that modify and alter the chromatin structure to influence the transcriptional activity. These coregulators are called corepressors when they suppress and coactivators when they enhance transcription of target genes. In addition, coactivator-associated proteins also exist that directly interact with coactivators and not with the nuclear receptors. More than 200 nuclear receptor coregulators (coactivators, corepressors, and coactivator-associated proteins) have been identified thus far. The extent to which a given cofactor regulates a specific nuclear receptor remains unclear (Feige and Auwerx, 2007; Yu and Reddy, 2007) . One of the best described cofactors in this respect is the transcriptional coactivator PPAR␥ coactivator 1␣ (PGC1␣) (Lin et al., 2005) . PGC1␣ binds to and coactivates most members of the nuclear receptor family, including PPAR␦. Overexpression of PGC1␣ in skeletal muscle (Lin et al., 2002) leads to effects on muscle metabolism similar to those of overexpression of an activated form of PPAR␦ ) (see discussion on fiber types in section III.A). The precise interaction between PPAR␦ and PGC1␣ remains to be clarified. PGC1␣ has been shown to synergistically coactivate PPAR␦ target genes in a PPAR␦-ligand-dependent manner (Kleiner et al., 2009) . Activation of PPAR␦ in skeletal muscle reportedly leads to increased PGC1␣ protein (Hancock et al., 2008) . The interaction between PGC1␣ and PPAR␦ is further modulated by the transcriptional regulator Twist-1 in adipose cells (Pan et al., 2009) , but whether this is also the case in skeletal muscle remains to be determined.
Silencing mediator for retinoic acid and thyroid hormone receptor (SMRT) and the nuclear receptor corepressor are corepressors that interact with the PPARs in the absence of ligands (DiRenzo et al., 1997; Zamir et al., 1997) . PPAR␦ is the only PPAR that associates with these corepressors when bound to DNA (Krogsdam et al., 2002) . It has been shown that PPAR␦ can repress PPAR␣-and PPAR␥-activated transcription by interaction with SMRT, histone deacetylases, and SMRT and histone deacetylase-associated repressor proteins (Shi et al., 2002) . Another ligand-dependent corepressor is RIP140, which interacts with many nuclear receptors including PPARs. RIP140 plays an important role in regulating metabolic processes in the myocytes, hepatocytes, and adipocytes . In skeletal muscle, reduction of RIP140 enhances expression of PPAR␦-dependent genes involved in mitochondrial activity and fiber-type determination (Seth et al., 2007) .
The corepressors possess or recruit histone deacetylases or other enzyme activities to keep a tight chromatin structure to repress gene transcription. When agonists bind to the receptors, coactivators are recruited. Coactivators are large proteins that contain one or more nuclear receptor boxes consisting of the conserved LXXLL (L, leucine; X, any amino acid) amphipathic ␣-helix consensus sequence that interacts with the AF-2 region in the PPARs. There are two different groups of coactivators: one group that possesses histone acetyltransferase or methyl transferase activities that remodel the chromatin structure and another group that enhances transcriptional activity by creating multiprotein complexes that form bridges between the nuclear receptors and the basal transcriptional machinery (Glass and Rosenfeld, 2000) . Examples of the former group that interacts with PPAR␦ include members of steroid hormone receptor coactivator family and PGC1␣ (Wang et al., 2003; Lim et al., 2004; Yu and Reddy, 2007) . The PPAR-binding protein belongs to the latter group of coactivator proteins that has been shown to bind to PPAR␦ (Lim et al., 2004) .
Taken together, the in vivo regulation of PPAR␦ during different conditions probably depends on the complex interplay between expression levels of the three PPARs and RXR isotypes; affinity for a specific PPRE, ligand, and cofactor availability; and possibly the binding of other transcription factors in the vicinity of the PPRE.
E. Regulation of Peroxisome Proliferator-Activated Receptor ␦ by Phosphorylation
Phosphorylation has been reported to alter transcriptional activity of both PPAR␣ and PPAR␥ (Burns and Vanden Heuvel, 2007) . Insulin increases serine phosphorylation of PPAR␣ (Shalev et al., 1996) and PPAR␥ (Zhang et al., 1996) via mitogen-activated protein kinase. Increased phosphorylation of PPAR␣ has been reported in response to activators of protein kinase A PPAR␦ IN SKELETAL MUSCLE (Lazennec et al., 2000) . Although similar phosphorylation sites are found in PPAR␦, the functional role of these sites has not yet been investigated.
F. Regulation of Peroxisome Proliferator-Activated Receptor ␦ Expression in Skeletal Muscle
As mentioned in section II.A, PPAR␦ is the most abundant PPAR isoform in skeletal muscle (Braissant et al., 1996; Muoio et al., 2002; de Lange et al., 2004) and has a higher expression in oxidative type I muscle fibers compared with glycolytic type II muscle fibers . A number of different physiological and pathological factors have been reported to influence skeletal muscle PPAR␦ content (Table 1 ). Both shortterm exercise (Watt et al., 2004; Mahoney et al., 2005) and endurance training (Russell et al., 2003; Fritz et al., 2006) lead to increased PPAR␦ expression in human and rodent skeletal muscle (Table 1) . A short period of muscle unloading (mimicking disuse such as bed rest) was also associated with increased PPAR␦ mRNA content (Mazzatti et al., 2008) . This increase was noted after 1 day of hind-limb unloading and had returned to control levels after 12 days, leading the authors to speculate that the increased expression of PPAR␦ after unloading represents an adaptive, stress-induced response to prevent further metabolic consequences (Mazzatti et al., 2008) , which is not maintained after longer-term muscle unloading. Indeed, skeletal muscle PPAR␦ mRNA content is reduced in the skeletal muscle of subjects with a long-standing spinal cord injury .
PPAR␦ also seems to be under nutritional control. Given the central role of PPAR␦ in controlling skeletal muscle lipid utilization, fasting, which results in a greater reliance on fatty acids, would be expected to increase PPAR␦ expression and/or activity. In line with this, a 6-, 24-, or 48-h starvation period results in a dramatic up-regulation of PPAR␦ mRNA in gastrocnemius muscle of mice (de Lange et al., 2006) , which is restored to control level upon refeeding . In contrast, 12-h fasting in rats did not alter PPAR␦ mRNA expression in skeletal muscle (but led to reduced PPAR␦ expression in kidney and liver) (Escher et al., 2001) . It is intriguing that down-regulation of human skeletal muscle PPAR␦ mRNA expression has been reported in healthy human subjects after a 48-h fast (Tsintzas et al., 2006) , but data from shorter food deprivation times in humans are lacking. Thus, it seems likely that after food deprivation, there is a rapid but transient increase in skeletal muscle PPAR expression. This correlates with a rapid nuclear accumulations of PPAR␦ and the coactivator PGC1␣ after food deprivation (de Lange et al., 2006) , which would subsequently lead to PPAR␦-mediated changes in genes regulating fatty acid metabolism.
Exercise training and fasting both lead to increased free fatty acids, making elevated fatty acids an attractive physiological signal regulating skeletal muscle PPAR␦ content. However, endurance exercise performed either in the fasted state (when fatty acids are high) or after carbohydrate ingestion (avoiding an increase in fatty acids) resulted in similar increases in skeletal muscle PPAR␦ mRNA expression, suggesting that contraction per se is the more important regulator (Russell et al., 2005) . Indeed, suppression of free fatty acids (using the antilipolytic drug nicotinic acid) actually increased mRNA expression of skeletal muscle PPAR␦ (Watt et al., 2004) . Furthermore, skeletal muscle PPAR␦ mRNA expression is reduced in subjects with spinal cord injury , a condition associated with elevated circulating free fatty acids. Incubation of cultured cells with different long-chain fatty acids, including palmitate, linoleate, and linolenate, have been reported to be without effect on PPAR␦ mRNA expression . A number of additional stimuli have also been reported to be without effect on PPAR␦ expression. These include isoproterenol, isobutyl methylxanthine, stable analogs of cyclic AMP, dexamethasone, cortisol, tri-iodothyronine, insulin in muscle cell cultures (Holst , 2003) , and in vivo insulin infusion during a 2-h hyperinsulinemic euglycemic clamp (Nilsson et al., 2007) . Thus, the physiological signals regulating the effects of nutritional status, and muscle use, remain to be identified. To date, the majority of data regarding regulation of PPAR␦ expression has relied on determination of mRNA, and it is possible that a clearer understanding will emerge as better antibodies allow reliable assessment of PPAR␦ protein content and, more importantly, the activation status of PPAR␦. Thus, it may be that presence of activating ligand is a more important physiological regulator than changes in total PPAR␦ content. Although the data regarding the effect of fatty acids on PPAR␦ expression are conflicting, circulating fatty acids are important regulators of PPAR␦ activity. Again, the precise nature of this regulation remains unresolved. Recent data indicate that the fatty acid transporter CD36 may facilitate entry of PPAR␦ ligands (Nahlé et al., 2008) . Because CD36 is itself a target gene of PPAR␦ (Table 2) , this would lead to a positive feedback to amplify PPAR␦ effects in the presence of activating ligand (Fig. 3) .
Skeletal muscle PPAR␦ expression has been reported to decline with age (Nilsson et al., 2007) . In line with a physiological role for PPAR␦ in enhancing lipid utilization, increased central adiposity was negatively correlated to skeletal muscle PPAR␦ mRNA (Nilsson et al., 2007) . Birth weight was found to be positively correlated to adult mRNA expression of skeletal muscle PPAR␦ (Nilsson et al., 2007) . Taken together, these data suggest that skeletal muscle PPAR␦ plays an important role in the regulation of whole-body metabolism.
III. Regulation of Skeletal Muscle Metabolic Phenotype and Fiber Types

A. Skeletal Muscle Fiber Types
Skeletal muscle is classified into different fiber types that have different metabolic and ergogenic characteristics. Skeletal muscle has traditionally been classified by physical appearance (that is, red and white) in recognition of the fact that this correlated with contractile properties ("slow" or "fast," respectively) (Brooke and Kaiser, 1970; Spangenburg and Booth, 2003) . The speed of muscle movement primarily depends on which isoform of myosin heavy chain (MHC) that is expressed in the muscle fiber (for review, see Harridge, 2007) . In human skeletal muscle, there are three isoforms of MHC: MHC-I, MHC-IIa, and MHC-IIx (rodents express IIb), in order of increasing speed of contraction. Skeletal muscle is thus usually classifies as type (MHC) I "slowred" and type IIa "fast red." So-called fast white muscles are categorized as IIx in humans and IIx and IIb in rodents (Spangenburg and Booth, 2003) . These classifications are also coupled to the metabolic profile of the muscle fibers, with oxidative slow-twitch fibers containing more mitochondria than the fast-twitch glycolytic fibers (Schiaffino and Serrano, 2002; Spangenburg and Booth, 2003) . In addition to increased mitochondrial content, insulin-stimulated glucose transport is also greater in slow-twitch muscle fibers than in fast-twitch glycolytic fibers, in part because of increased expression of glucose transporters and insulin signaling intermediates (Henriksen et al., 1990; Song et al., 1999; Daugaard et al., 2000) . Furthermore, because whole-body insulin sensitivity is positively correlated with the proportion of slow-twitch oxidative fibers in humans (Lillioja et al., 1987) , interest has focused on understanding the molecular regulation of muscle fiber types with the aim of using these targets to enhance insulin sensitivity.
B. Peroxisome Proliferator-Activated Receptor ␦ Is a Key Gene in the Regulation of Skeletal Muscle Fiber Types
The use of transgenic animals has given important insights into the molecular regulation of skeletal muscle fiber types. One of the first genes to be implicated as important for fiber-type regulation was PGC1␣. Targeted muscle expression of PGC1␣ in mice resulted in a conversion of muscles normally rich in type II fibers to a slower oxidative type I muscle phenotype (Lin et al., 2002) . In a similar manner, PPAR␦ was also shown to play a key role in the development of oxidative type I fibers. Transgenic mice with targeted skeletal muscle overexpression of either the wild type or an activated form ) of the PPAR gene have an increased proportion of type I muscle. Furthermore, mice with reduced expression (null or heterozygous) of the RIP140 corepressor have increased formation of type I muscle fibers, whereas transgenic overexpression reduces type I muscle fibers (Seth et al., 2007) . Thus, increased expression of PPAR␦ or its coactivator PGC1␣, or the reduction of the RIP140 corepressor, enhances formation of type I fibers, suggesting a key role for alterations in PPAR␦ activity in the regulation of muscle fiber type. Indeed, mice in which PPAR␦ has been selectively ablated from muscle have fewer type I muscle fibers (Schuler et al., 2006) . These PPAR␦-ablated mice also have reduced skeletal muscle expression of PGC1␣, suggesting that PPAR␦ may regulate at least the basal expression of one of its own important cofactors (Schuler et al., 2006) .
It is important to keep in mind that fiber-type regulation in transgenic animals is a result of changed mRNA expression during actual muscle development. Whether similar processes are involved in fiber-type regulation in mature muscle remains to be determined. Although the PPAR␦/PGC1␣-dependent signals seem to play important roles in the induction/maintenance of slow oxidative type I fibers, other regulators have also been implicated. These include, for example, the phosphatase calcineurin (Chin et al., 1998; McCullagh et al., 2004) . However, pharmacological inhibition of cal-PPAR␦ IN SKELETAL MUSCLE cineurin by cyclosporin A results in impaired PPAR␦-mediated induction of changes in myofiber metabolic phenotype (Gaudel et al., 2008) , indicating a cross-talk between these different pathways. Finally, it is worth remembering that significant differences exist between rodent and human skeletal muscle with regard to fibertype homogeneity/regulation and degree of skeletal muscle fiber-type transformation (Holloszy and Coyle, 1984; Delp and Duan, 1996) . There is little evidence that switching between type II and type I muscle fibers actually happens in adult humans (Holloszy and Coyle, 1984; Delp and Duan, 1996; Harridge, 2007) ; thus, care Muoio et al., 2002; Dressel et al., 2003; Tanaka et al., 2003; Wang et al., 2004; Jucker et al., 2007; Krämer et al., 2007; Sprecher et al., 2007; Narkar et al., 2008; Risérus et al., 2008; Kleiner et al., 2009 Cytochrome C Muoio et al., 2002; Dressel et al., 2003; Tanaka et al., 2003; Abbot et al., 2005; Constantin et al., 2007; Jucker et al., 2007; Krämer et al., 2007; Sprecher et al., 2007; Narkar et al., 2008; Kleiner et al., 2009 (Kiens, 2006; Houmard, 2008) . In the fasted state, fatty acid oxidation is the foremost metabolic activity of skeletal muscle (Dagenais et al., 1976; Houmard, 2008) . Thus, factors regulating skeletal muscle fatty acid oxidation will affect whole-body homeostasis. Plasma-free fatty acids enter the skeletal muscle cell either via diffusion through the plasma membrane or via receptor proteins in the plasma membrane, including CD36m, FABPpm, and FATP1. Once inside the cell, fatty acids are activated in the cytosol by reaction with CoA and ATP to form fatty acyl-CoA complexes, which may then enter the mitochondria for subsequent oxidation. The entry of longchain fatty acyl-CoAs into the mitochondrion is facilitated by carnityl palmitoyl transferase, the activity of which is allosterically regulated by malonyl-CoA. For a more detailed review of these processes, see Kiens (2006) . A number of key genes involved in fatty acid entry into the myocyte and subsequent oxidation have been shown to be target genes for PPAR␦ (see Table 2 ). Thus, one of the most direct measurable metabolic effects of PPAR␦ activation is increased fatty acid oxidation, which is evident both in cultured cell models in vitro (Muoio et al., 2002; Sprecher et al., 2007; Kleiner et al., 2009 ), isolated skeletal muscle (Brunmair et al., 2006) , and in vivo (Tanaka et al., 2003; Wang et al., 2003 Wang et al., , 2004 Constantin et al., 2007; Jucker et al., 2007) . The enhanced oxidation of lipids in skeletal muscle probably explains why PPAR␦ activation is particularly effective in protecting against the consequences of dietary lipid overload (Tanaka et al., 2003; Wang et al., 2003 Wang et al., , 2004 .
2. Peroxisome Proliferator-Activated Receptor ␦ Regulates Muscle Fuel Utilization. Increased PPAR␦ activation increases skeletal muscle lipid oxidation and regulates a number of genes involved in lipid oxidation. Key proteins in this respect are carnityl palmitoyl transferase, CD36, and pyruvate dehydrogenase kinase (PDK). PDK has four isozymes. PDK phosphorylates, resulting in the inactivation of the pyruvate dehydrogenase complex (PDC). This is the rate-limiting step in muscle carbohydrate oxidation. Increased PDK4 expression thus leads to PDC inhibition and reduced carbohydrate oxidation. Thus, PDC inhibition is a pivotal point that can alter fuel selection in skeletal muscle toward fat oxidation. Skeletal muscle contains two PDK isoforms, PDK2 and PDK4 (Holness et al., 2000) . PDK4 has consistently been reported as a key target gene in response to PPAR␦ activation (Table 2) . Recent functional analysis indicates that PDK2, PDK3, and PDK4 are primary PPAR␦ target genes in humans, with several PPRE rec- FIG. 3 . PPAR␦-mediated changes in gene expression lead to increased lipid oxidation: free fatty acids (FFA) enter skeletal muscle via the CD36 fatty acid transporter, for example, leading to activation of PPAR␦-dependent genes. This includes PDK4, which reduces glucose oxidation, and several genes important for fatty acid oxidation. CD36 is itself also a PPAR␦-dependent gene.
PPAR␦ IN SKELETAL MUSCLE ognition sequences in the promoters (Degenhardt et al., 2007) . Exercise-induced PDC inhibition is much more potent in rats treated with the PPAR␦ agonist GW610742 (Constantin-Teodosiu et al., 2009) , which probably depends on the PPAR␦-driven enhanced PDK4 expression. In addition to enhanced expression of PDK, PPAR␦ activation concomitantly leads to increased expression of genes involved in uptake (such as CD36) and oxidation of fatty acids. Indeed, a direct functional interplay between PPAR␦, CD36, and PDK4 has been proposed (Nahlé et al., 2008) , such that CD36 mediates uptake of fatty acids required for activation of PPAR␦, which in turn leads to increased expression of PDK4, and further increased expression of CD36. Thus, during fasting, when there are increased circulating fatty acids, this would lead to activation of PPAR␦, which would alter metabolism to spare glucose and enhance lipid oxidation. Here, it is noteworthy that although fastingmediated induction of PDK4 is unaltered in skeletal muscle from PPAR␣-null mice (Muoio et al., 2002) , it is markedly blunted in skeletal muscle from PPAR␦-null mice (Nahlé et al., 2008) . This suggests that PPAR␦ is the primary isoform involved in regulating muscle fuel utilization in response to fasting.
3. Peroxisome Proliferator-Activated Receptor ␦ and Mitochondrial Function. Evidence from transgenic mice with enhanced PPAR␦ function indicates that PPAR␦ may play a key role in the regulation of mitochondrial function Wang et al., 2004) . Mammalian mitochondrial biogenesis is subject to complex physiological control (Scarpulla, 2008) . Treatment with specific PPAR␦ agonists leads to increases of the expression of several genes involved in the pathway for fatty acid oxidation within the mitochondrial matrix that oxidizes fatty acids to acetyl-CoA (Table 2). Genes directly regulating mitochondrial biogenesis have not been reported to be classic PPAR␦ target genes (Scarpulla, 2008) . The PPAR␦ coactivator PGC1␣, however, is a master regulator of mitochondrial biogenesis (Wu et al., 1999; Handschin and Spiegelman, 2008) . Although PGC1␣ mRNA expression is not changed after overexpression of PPAR␦ in transgenic mice Wang et al., 2004) , transient overexpression of PPAR␦ in mouse skeletal muscle has been shown to result in increased PGC1␣ protein content (again without affecting PGC1␣ mRNA), concomitant with enhanced mitochondrial content (Hancock et al., 2008) . Because of technical antibody-dependent challenges in correct quantification of PGC1␣ protein, many studies have relied on measuring PGC1␣ mRNA; thus, a PPAR␦-dependent post-translational effect on PGC1␣ protein may have been missed. In support of a direct PPAR␦-PGC1␣ interaction, in skeletal muscle cells established from mice lacking PGC1␣, the ability of PPAR␦ activators to increase fatty acid oxidation was reduced (Kleiner et al., 2009 ). The maximal rates of ATP production in isolated mitochondria from soleus muscle was unchanged after administration of PPAR␦ agonist (GW610742) for 6 days to Wistar rats (Constantin et al., 2007) . Taken together, current evidence suggests that PPAR␦ activation leads to increased mitochondrial numbers via PGC1␣-dependent pathways but does not affect mitochondrial function per se. The precise nature of PPAR␦-mediated increases in mitochondria numbers and biogenesis remains to be resolved.
4. Does Peroxisome Proliferator-Activated Receptor ␦ Activation Alter Skeletal Muscle Glucose Uptake? One of the key target genes of activated PPAR␦ is PDK4, the expression of which leads to reduced carbohydrate oxidation; thus, the expectation would be that activation of PPAR␦ reduces glucose oxidation. In line with this, in isolated rat skeletal muscle incubated in vitro, an shortterm activation of PPAR␦ was without effect on glucose transport (Terada et al., 2006) . The metabolic improvements noted in animal models (obese animal models or animals challenged with a high-fat diet; see section IV.A for a complete discussion) could be due to indirect effects on whole-body metabolism after resolution of excessive lipid deposition. There are reports, however, that activation of PPAR␦ may have direct effects that increase muscle glucose uptake. For example, we have reported that exposure of human skeletal muscle cells and C2C12 cells to a PPAR␦ agonist increased glucose uptake in a PPAR␦-dependent manner (Krä mer et al., 2005 , which further depended on the presence of functional AMP-activated protein kinase (AMPK) on the cells. Furthermore, in an elegant in vivo study of tissue glucose uptake with use of positron emission tomography scanning, single-nucleotide polymorphisms (SNPs) of PPARD were linked to insulin sensitivity with respect to glucose uptake (Vä nttinen et al., 2005) . This was true for skeletal muscle glucose uptake but not for adipose tissue glucose uptake (Vä nttinen et al., 2005) . Further indirect evidence that PPAR␦ may directly enhance glucose metabolism comes from treatment studies in which administration of PPAR␦ agonists has been reported to reduce fasting insulin levels. However, further studies are warranted to directly determine the role of PPAR␦ on skeletal muscle glucose uptake.
Peroxisome Proliferator-Activated Receptor ␦ and Adenosine Monophosphate-Activated Protein Kinase.
AMPK is an energy sensor that is activated when cell energy states are low (Long and Zierath, 2006) . When activated, AMPK stimulates glucose uptake and lipid oxidation to produce energy while turning off energyconsuming processes. Muscle contraction has been shown to increase AMPK activity. It is noteworthy that AMPK is constitutively activated in muscles of transgenic mice harboring an activated form of PPAR␦ (Narkar et al., 2008) . We have also noted an increase in AMPK activity in skeletal muscle cells exposed to pharmacological PPAR␦ activator (Krä mer et al., 2005 . Coimmunoprecipitation of PPAR␦ and the catalytic subunits of AMPK (␣1 or ␣2) has been reported when PPAR␦ is 382 EHRENBORG AND KROOK overexpressed (Narkar et al., 2008) , suggesting a direct physical interaction between these two molecules. Although such an interaction has not yet been demonstrated with endogenous PPAR␦, this suggests that there may be a cross-talk between AMPK and PPAR␦-dependent signaling pathways, and it could explain how PPAR␦ activation leads to increased glucose uptake and metabolism.
D. Peroxisome Proliferator-Activated Receptor ␦ and Muscle Performance
The regulation of fiber types is complex, and some of this complexity derives from the difficulty in defining a fiber type. Indeed, the MHC classification system described in section III.A is just that: a way of grouping muscle fibers depending on the isoform of MHC expressed, but it conveniently also allows grouping into physiologically relevant subtypes. There is evidence that some fibers express more than one MHC isoform (Talmadge, 2000) . With this caveat in mind, it remains relevant to consider that fiber-type composition has a direct influence on exercise performance, and there is also some evidence that exercise training may in turn influence fiber type. Indeed, some of the key factors implicated in the regulation of muscle fiber type are also known to be regulated by exercise training in mature muscle, including PPAR␦ and PGC1␣.
Mouse models with muscle-specific PPAR␦ overexpression have increased endurance capacity Wang et al., 2004) . Mice expressing active PPAR␦ in muscle were affectionately nicknamed "marathon mice" because they were able to run twice as far and for twice as long as their wild-type littermates . It is noteworthy that this enhanced running capacity is inherent in the PPAR␦-overexpressing mice, and it is not due to altered behavior making them more physically active. Furthermore, in wild-type mice, 6 weeks of exercise training (a 45-min swim per day, 5 days per week) resulted in up-regulation of PPAR␦ protein in the tibialis anterior muscle . Increased expression of PPAR␦ protein after exercise training has also been reported in human studies (Russell et al., 2003; Watt et al., 2004; Mahoney et al., 2005; Fritz et al., 2006) .
A curious finding in this context is the report that administration of PPAR␦ agonist (GW610742) for 6 days to Wistar rats increased expression of the muscle-specific E3 ligases MAFbx and MuRF1 (Constantin et al., 2007) . Up-regulation of MAFbx and MuRF1 has been linked to muscle catabolism (Lecker et al., 2004) .
Nutritional status may influence the exercise effect on PPAR isoforms. As discussed in section II.F, fasting dramatically increases PPAR␦ mRNA expression in mice . Fasting is associated with increased circulating free fatty acids; however, nicotinic acid-mediated reduction in circulating free fatty acids increased PPAR␦ mRNA expression in human skeletal muscle (Watt et al., 2004) . In the latter case, exercise in the presence of nicotinic acid was not able to further increase skeletal muscle PPAR␦ mRNA (Watt et al., 2004) . Given the additional complexity of hormonal and nutrient regulation of these targets, dissecting exercise from nutritional effects on PPAR expression may be a challenge. Because PPAR␦ expression is not the only determinant of PPAR␦ activity, exercise-mediated effects on cofactors and on possible natural activating ligands may also contribute to the regulation of PPAR␦-directed gene-regulatory events.
In addition to enhancing expression of genes required for lipid oxidation and myogenic markers, pharmacological activation of PPAR␦ in adult mice has recently been linked to a rapid and transient up-regulation of angiogenic markers (VEGF-A and PECAM-1) (Gaudel et al., 2008) . In a mouse ischemic hind limb model, PPAR␦ agonist treatment resulted in improved vasculogenesis via regulation of endothelial progenitor cells, highlighting the potential for PPAR␦ agonism as a novel option for treatment of ischemic cardiovascular diseases . Enhanced capillarization of skeletal muscle is a physiological response to endurance training. It is noteworthy that capillarization was more pronounced in animals treated with a PPAR␦ activator than in the muscles of PPAR␦-overexpressing mice (animals expressing PPAR␦ specifically in skeletal muscle) (Piqueras et al., 2007) . The reported angiogenic response thus may be limited to a subgroup of muscle fibers or may involve other cell types, such as endothelial cells.
E. Peroxisome Proliferator-Activated Receptor ␦ Effects in Cardiac Muscle
In parallel with the effects noted in skeletal muscle, PPAR␦ also has important effects on cardiac muscle. PPAR␦ mRNA is abundantly expressed in cardiomyocytes, where it regulates genes involved in fatty acid oxidation and lipid metabolism (Gilde et al., 2003) . Cardiomyocyte-specific deletion of Ppard in mice results in cardiac dysfunction characterized by myocardial fat accumulation, cardiac hypertrophy, and finally heart failure. Furthermore, transgenic mice overexpressing PPAR␦ specifically in the heart are resistant to myocardial lipid accumulation on a high-fat diet and show no signs of cardiac dysfunction (Cheng et al., 2004) . These PPAR␦-overexpressing mice show increased cardiac glucose uptake and oxidation rates concomitant with increased GLUT4 gene expression. Moreover, the expression of genes involved in fatty acid oxidation are increased in the heart of the cardiac-specific PPAR␦-overexpressing mice; surprisingly, however, show no difference in fatty acid uptake or oxidation compared with wild-type control animals (Burkart et al., 2007) . Thus, the relative protection from ischemia-reperfusion injury noted in these mice is probably due to an increased capacity for myocardial glucose utilization, which is a biological response to hypoxia (Opie and Sack, 2002) PPAR␦ IN SKELETAL MUSCLE
IV. Peroxisome Proliferator-Activated Receptor ␦ and Metabolic Disease
A. Peroxisome Proliferator-Activated Receptor ␦ Agonists and Treatment of Metabolic Disease
Given the ability of PPAR␦ agonists to increase fatty acid catabolism, cholesterol efflux, and energy expenditure in muscle, interest has focused on therapeutic utility in the treatment of hyperlipidemia, atherosclerosis, and obesity. Diabetic dyslipidemia is characterized by high levels of triglyceride-rich, very-low-density lipoprotein particles and their cholesterol ester-rich remnant particles, low levels of high-density lipoprotein (HDL) cholesterol, and small dense low-density lipoproteins (Adiels et al., 2006) . Our present knowledge regarding PPAR␦ in relation to metabolic diseases is based to a large extent on genetically modified animals and the use of high-affinity synthetic ligands for PPAR␦, but it is also based on a few studies in humans and in vitro-based approaches.
Both the genetic leptin-resistant (db/db) and the leptin-deficient (ob/ob) mice are obese/diabetic animal models that have been investigated in relation to how PPAR␦ exerts its metabolic effects. One of the first studies using a synthetic PPAR␦ ligand in an obese and diabetic animal model was performed in db/db mice (Leibowitz et al., 2000) . In these mice, treatment with the PPAR␦ agonist L-165041 improved the lipid profile by increasing the HDL cholesterol concentration, but the treatment had little or no effect on plasma glucose or triglyceride levels. Because the L-165041 is only a weak agonist of the murine PPAR␦, other more potent PPAR␦ ligands were developed (Willson et al., 2000) . Use of the potent and high-affinity synthetic PPAR␦ ligands in different animal models and in human studies showed that activation of PPAR␦ can promote reversal of metabolic abnormalities (Oliver et al., 2001; Jucker et al., 2007; Chen et al., 2008; Gaudel et al., 2008; Risérus et al., 2008; Kleiner et al., 2009 ). The diet-induced obesity that mice fed a high-fat diet develop could be prevented by treatment with GW501516 because of enhanced fatty acid utilization and energy expenditure (Tanaka et al., 2003) . Although GW501516 treatment had no effects on blood glucose levels, the concentrations of plasma insulin decreased regardless of diet. Both glucose tolerance and insulin sensitivity were improved in these animals, and lipid accumulation in both skeletal muscle and liver were decreased. Leptin-deficient obese and diabetic ob/ob mice also showed improved glucose tolerance and reduced plasma insulin concentrations after treatment with GW501516 (Tanaka et al., 2003) . Injection of monosodium L-glutamate results in the development of metabolic syndrome in mice. In this model, insulin resistance and dyslipidemia improved, and hyperleptinemia decreased after treatment with a specific PPAR␦ agonist . Spontaneously obese, insulin-resistant middle-aged rhesus monkeys treated with the PPAR␦ activator GW501516 displayed augmented serum HDL-cholesterol concentrations accompanied by decreased levels of small dense low-density lipoproteins, triglyceride, and insulin (Oliver et al., 2001) . Furthermore, GW501516 treatment lowered the fasting plasma insulin without changing glucose levels. Many of the improvements in metabolic profiles noted in response to PPAR␦ agonists are mirrored in mice with transgenic overexpression of PPAR␦ specifically in skeletal muscle Wang et al., 2004) , indicating that skeletal muscle may be a primary target organ. Effects on other tissues should not be ruled out, however. For example, activation of PPAR␦ in adipose tissue leads to improved lipid profiles, decreased lipid accumulation, and reduced adiposity. These transgenic mice are also resistant to obesity induced by a high-fat diet (Wang et al., 2003) . The beneficial metabolic effects observed in these animals may also be due in part to a PPAR␦-mediated alternative activation of adipocyte macrophages and hepatic Kupffer cells . It has been suggested that resident macrophages in adipose tissue and liver are important in controlling energy metabolism and insulin action by coordinating the classic (M1) and alternative (M2) programs of activation (Xu et al., 2003; . The M1-activated macrophages are proinflammatory and the M2-activated macrophages are anti-inflammatory. Stimulation with interferon ␥ and lipopolysaccharides activates M1 macrophages, whereas interleukins 4 and 13 activate M2 macrophages and PPAR␦ . PPAR␦-deficient macrophages are unable to shift to the M2 phenotype, resulting in hepatic fat accumulation, decreased fatty acid ␤-oxidation, and increased insulin resistance in liver and skeletal muscle . Activation of PPAR␦, which also has been shown to regulate transition from classic to alternative macrophage phenotypes, was not able to compensate for the loss of M2 activation in PPAR␦-deficient macrophages . Recent data, however, indicate that, in human atherosclerotic plaques and primary human macrophages, mRNA expression of PPAR␦ does not correlate with mRNA expression of M2 markers (Bouhlel et al., 2009 ). Thus, there may be species differences regarding the effects of PPAR␦ in macrophages, underscoring again the idea that caution is warranted when drawing conclusions regarding human physiology based on murine observations.
The currently available data regarding the impact of PPAR␦ activation on changes in body weight is ambiguous. Although GW501516 prevents weight gain in mice with diet-induced obesity and in ob/ob mice (Tanaka et al., 2003) , this was not seen in db/db mice or ZUCKER fa/fa obese rats (Pelton, 2006) . Other studies showed no effect on body weight during PPAR␦ agonist treatment (Oliver et al., 2001; Chen et al., 2008) . PPAR␦-deficient 384 EHRENBORG AND KROOK mice show reduced adipose stores compared with wildtype animals (Peters et al., 2000; Tan et al., 2001; Barak et al., 2002) , whereas mice carrying an adipose tissuespecific deletion of PPAR␦ showed no reduction in adiposity, showing that the adipose tissue responds to an exogenous stimulus, rather than to the receptor within the fat cell (Barak et al., 2002) . However, Ppard knockout mice fed a high-fat diet showed increased adiposity, despite lower total body weight (Akiyama et al., 2004) . Furthermore, Ppard knockout animals are glucose intolerant, have a decreased metabolic rate, and are not responsive to treatment with GW501516 (Tanaka et al., 2003; Luquet et al., 2004; Lee et al., 2006) .
The positive influences on metabolic endpoints obtained in animal studies seem to hold up in the few human treatment studies published so far (Sprecher et al., 2007; Metabolex, 2008; Risérus et al., 2008; Christodoulides et al., 2009) , the outcomes of which are summarized in Table 3 . Young healthy subjects treated with GW501516 for 2 weeks reported no significant adverse effects, including liver and muscle responses. In this small group, the PPAR␦ agonist lowered plasma triglyceride and increased HDL concentrations (Sprecher et al., 2007) . Treatment with the PPAR␦ agonist GW501516 for 2 weeks in healthy and moderately obese subjects led to reduction of plasma triglyceride, LDL cholesterol, and apolipoprotein B levels accompanied by decreased liver fat content and increased plasma fibroblast growth factor 21 levels (Risérus et al., 2008; Christodoulides et al., 2009) . Despite the fact that the participants in these studies were healthy and glucose tolerant, there was a reduction in fasting glucose and improved insulin sensitivity. There is limited information regarding the effects of a novel PPAR␦-targeting compound MBX-8025 (Metabolex, 2008) ; however, an 8-week trial reported reduced triglycerides, LDL, insulin, and glucose. It is noteworthy that there have been no reports of adverse reactions in any of the studies to date, and no increase of oxidative stress has been detected, probably because of increased fat oxidation in skeletal muscle (Risérus et al., 2008) .
B. Single-Nucleotide Polymorphisms in Peroxisome Proliferator-Activated Receptor ␦ Have Been Linked to Altered Lipid Profiles
Over the past couple of years, there has been an increased focus on activation of PPAR␦ to unravel its function. Considerably less is known about the regulation of PPAR␦ expression per se and the physiological consequences of genetic variation within PPARD. Because PPAR␦ is an important regulator of genes involved in lipid and glucose metabolism, one might expect polymorphisms in PPARD to be associated with the metabolic syndrome, type 2 diabetes, obesity, and/or cardiovascular disease. Several association studies on the role of PPARD polymorphisms in relation to metabolic dysfunction and risk for diabetes and cardiovascular disease have been published (Skogsberg et al., 2003a,b; Shin et al., 2004; Gouni-Berthold et al., 2005; Vä nttinen et al., 2005; Aberle et al., 2006a,b; Andrulionyte et al., 2006; Hu et al., 2006; Grarup et al., 2007; Hautala et al., 2007; Robitaille et al., 2007; Stefan et al., 2007; Lagou et al., 2008; Sá ez et al., 2008; Thamer et al., 2008) . More than 16 SNPs in PPARD have been analyzed thus far, and the majority of these relatively large association studies have investigated a polymorphism in exon 4, rs2016520, located 87 base pairs upstream of the translational start site. Figure 4 shows the three different haploblocks covering the PPARD locus obtained from public databases.
An initial study (Skogsberg et al., 2003a ) that we conducted suggested that SNP rs2016520 in exon 4 was of functional relevance, influencing the binding of Sp-1 and subsequent transcriptional activity. The minor C allele was associated with increased plasma LDL concentrations in 543 healthy middle-aged men (Skogsberg et al., 2003a) . Considering the effect on plasma LDL concentrations, the effect on the incidence of myocardial infarction was assessed in the West of Scotland Coronary Prevention Study, consisting of men with hyperlipidemia and an increased risk of cardiovascular disease. Although subjects homozygous for the C allele showed only a tendency toward increased risk for coronary heart disease, and any major effect of the SNP in this respect could be excluded, an association between decreased HDL cholesterol concentrations in plasma and the minor C allele of the rs2016520 polymorphism was found (Skogsberg et al., 2003b) . The impact of the rs2016520 polymorphism on HDL concentrations has been confirmed in a group of almost 1000 female patients with mixed hyperlipidemia (Aberle et al., 2006b) . Relationships between the rs2016520 SNP and lipid levels and coronary lesions have also been investigated in the Lipoprotein and Coronary Atherosclerosis Study, consisting of 372 subjects that have had at least one coronary lesion. Significant associations between the minor C allele and increased plasma apolipoprotein B, total cholesterol, and triglyceride concentrations along with the maximum number of lesions were found (Chen et al., 2004) . On the other hand, the rs2016520 in exon 4 showed no association with plasma lipid concentrations, body mass index (BMI), and atherosclerotic disease in a cohort consisting of 402 patients with type 2 diabetes 
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and 436 nondiabetic control subjects (Gouni-Berthold et al., 2005) . Thus, taken together, no major influence of SNPs in PPARD on risk for coronary heart disease has been shown. This is in accordance with the data obtained from genome-wide association studies (GWAS), which have not identified PPARD as a risk gene for myocardial infarction.
A number of relationships between body fat and BMIrelated phenotypes and polymorphisms in the PPARD have also been reported. An association of the minor C allele of the same rs2016520 polymorphism in exon 4 discussed in relation to lipoprotein regulation with a higher percentage of body fat in 376 nondiabetic Chinese subjects has been detected (Hu et al., 2006) . In line with this finding is the report regarding a polymorphism located in exon 7 (rs2076167) that showed an odds ratio of 1.43 with respect to obesity in a case-control study comprising 725 obese subjects (BMI Ͼ 30) and 1228 nonobese control subjects (Sá ez et al., 2008) . Furthermore, a common haplotype including the major alleles of rs2016520 in exon 4 and rs1053049 in exon 9 has been shown to be associated with higher BMI in 249 nondiabetic control subjects from Korea (Shin et al., 2004) . However, when all of these SNPs were tested in a large study comprising three cohorts consisting of 7495 white subjects, including 1416 subjects with type 2 diabetes, no associations of tag SNPs with either lipid concentrations or BMI were found (Grarup et al., 2007) . Furthermore, a recent study in 2102 Greek children aged 1 to 6 years failed to detect any associations between the rs2016520 in exon 4 and adiposity measures (Lagou et al., 2008) . The two latter studies are probably the only ones to date that have the statistical power to detect an association with obesity. It is noteworthy that none of the recent GWAS have identified the PPARD as an obesity gene.
The association between type 2 diabetes and polymorphisms in PPARD has also been investigated. A genetic variant in intron 2 (rs69021239) was associated with an increased risk of conversion from impaired glucose tolerance to type 2 diabetes in female subjects, but not male subjects, in the STOP-NIDDM trial consisting of 769 middle-aged subjects during a 5-year follow-up period. This risk was more pronounced in combination with SNPs of the PPARGC1A and PPARG2 genes (Andrulionyte et al., 2006) . On the other hand, Grarup et al. (2007) found no major effect of SNPs in PPARD on the risk for type 2 diabetes. Again, this is in line with the absence of finding the PPARD in GWAS for type 2 diabetes. Although the study by Grarup et al. (2007) did identify a haplotype containing minor alleles of rs2076169 (intron 5) and rs2076167 (exon 7) that were associated with increased insulin sensitivity, after correction for multiple hypothesis testing, the association was no longer statistically significant.
Because PPAR␦ is considered to act as a metabolic sensor, the influence of PPARD SNPs in relation to changes in diet have been investigated. There is considerable environmental influence on the impact of PPAR␦-associated risks. Dietary fat intake has been shown to influence the relationship between the PPARD exon 4 SNP rs2016520 and the risk of having three or more components of the metabolic syndrome in 340 subjects (Robitaille et al., 2007) . Individuals consuming less than 34.4% of energy from fat were protected against features of the metabolic syndrome, which is of interest considering the high binding affinity of long-chain fatty acids as potential ligands for PPAR␦.
In summary, there is no clear evidence that genetic variation in the PPARD has a major effect on myocardial infarction, obesity, or type 2 diabetes; however, the observation that PPARD SNPs interact with nutrients, and possible response to physical activity, suggests that genetic variation in the PPARD may determine metabolic response to external factors, such as diet and exercise. These possible connections require further study.
C. Single-Nucleotide Polymorphisms in Peroxisome Proliferator-Activated Receptor ␦ in Relation to Skeletal Muscle Function and Physical Performance
Based on the roles that PPAR␦ plays in muscle fiber composition and mitochondrial oxidative pathways involving fatty acid oxidation and oxidative phosphorylation, several genetic association studies have been performed in relation to function of the skeletal muscle. The relationship between PPARD SNPs and glucose uptake was investigated in 129 healthy individuals by use of the hyperinsulinemic-euglycemic clamp technique combined with fluorine-18-labeled fluorodeoxyglucose and positron emission tomography. Three SNPs of PPARD and a haplogenotype of these variants were significantly associated with increased insulin-stimulated wholebody and skeletal muscle glucose uptake but not with subcutaneous adipose tissue glucose uptake (Vä nttinen et al., 2005) .
The impact of the polymorphisms rs2016520, in exon 4, and rs2076167, in exon 7, has been investigated in response to regular exercise in sedentary healthy black (n ϭ 264) and white subjects (n ϭ 477) (Hautala et al., 2007) . After 20 weeks of endurance training, black subjects homozygous for the minor C allele of rs2016520 showed a significantly lower training-induced increase in maximal oxygen consumption and maximal power output compared with carriers of the major T allele. A similar trend was also observed in white subjects. Endurance training depends on the capacity of skeletal muscle fat oxidative capacity, and any constitutive or induced reduction in PPAR␦ function or expression might impair the ability to adequately up-regulate fat oxidation in skeletal muscle. In addition, both polymorphisms were associated with plasma HDL concentrations that were influenced by endurance training (Hautala et al., 2007) .
PPAR␦ IN SKELETAL MUSCLE
How genetic variants of PPARD influence changes in aerobic physical fitness, insulin sensitivity, and body composition have been studied in persons with an increased risk for type 2 diabetes who participated in a 9-month exercise and dietary lifestyle intervention program. The minor alleles of three SNPs rs6902123 (intron 2), rs2267668 (intron 3), and rs1053049 (exon 9) have been shown to be associated with reduced response to the lifestyle intervention resulting in a smaller increase in relative muscle volume, and a reduced decrease in adipose tissue mass and ectopic fat storage in liver (Thamer et al., 2008) . Carriers of the minor G allele of rs2267668 had a smaller increase in individual anaerobic threshold, a precise measurement of aerobic physical fitness, compared with homozygous carriers of the major A allele. Moreover, individuals carrying the minor C allele of the rs1053049 had a smaller reduction in fasting insulin levels compared with subjects homozygous for the major T allele (Thamer et al., 2008) . A separate analysis of this cohort detected an additive effect of the rs2267668 (exon 3) and the Gly423Ser polymorphism in the PPARGC1A, resulting in an even smaller increase in the individual anaerobic threshold and insulin sensitivity (Stefan et al., 2007) . Analyses of skeletal muscle mitochondrial activity in cultured myotubes obtained from healthy young subjects showed that carriers of the minor G allele of rs2267668 had lower mitochondrial function compared with subjects homozygous for the major A allele (Stefan et al., 2007) . Overall, these studies suggest that PPARD SNPs might be of importance in predicting the effectiveness of lifestyle interventions and energy utilization in skeletal muscle, but most studies to date are rather small and need to be replicated.
D. Is Skeletal Muscle Peroxisome Proliferator-Activated Receptor Expression Altered in Metabolic Disease?
We have reported recently that skeletal muscle protein expression of PPAR␦ increased significantly after physical exercise in patients with type 2 diabetes after a 4-month low-intensity exercise program (Fritz et al., 2006) . It is noteworthy that an increase in skeletal muscle protein expression of PPAR␦ was associated with improvements in several clinical parameters; PPAR␦ expression was unchanged in subjects who did not improve their clinical profile after exercise. Increased skeletal muscle PPAR␦ mRNA expression has been noted in healthy, glucose-tolerant subjects undergoing biliopancreatic diversion (enhancing insulin sensitivity and glucose oxidation); however, in subjects with type 2 diabetes, there was a blunted increase in glucose oxidation and no increase in skeletal muscle PPAR␦ mRNA expression after biliopancreatic diversion (Herná ndez- Alvarez et al., 2009) . Taken together with results indicating that polymorphisms in the PPARD may affect exercise response, this suggests that PPAR␦ may be one key factor coordinating exercise-mediated changes in metabolism. These data also suggest a direct implication of PPAR␦ in the muscle remodeling that occurs during endurance training and possibly in the beneficial effects of exercise on metabolic syndrome.
V. Concluding Thoughts
A. What Will Be the Therapeutic Impact of Peroxisome Proliferator-Activated Receptor ␦ Agonists?
Drugs directed against PPAR␣ (fibrates) and PPAR␥ (thiazolidinediones) have proven to be efficacious therapy against hyperlipidemia and type 2 diabetes/insulin resistance, respectively. In this review, we have focused on the effects of PPAR␦ in skeletal muscle. As suggested in Fig. 5 , physiological activation of PPAR␦ occurs when there is an increased need for skeletal muscle lipid utilization, leading to a number of adaptations that have a positive impact in insulin resistance. PPAR␦ differs from PPAR␣ and PPAR␥ in that it has a wider tissue-specific expression pattern and it has direct effects on skeletal muscle metabolism. Because the effects of PPAR␦ have been studied less intensively than those of PPAR␣ and PPAR␥, less is also known regarding safety issues. In a genetically modified animal model, intestinal tumorigenesis, but not colon carcinogenesis, was increased in response to GW501516 (Gupta et al., 2004) . On the other hand, mice lacking PPAR␦ have an increased predisposition to intestinal tumors (Reed et al., 2004) ; other reports suggest that ligand activation of PPAR␦ is without effect (Hollingshead et al., 2007) or, in fact, inhibits growth of human cancer cell lines (Bility et al., 2008; Borland et al., 2008) and colon carcinogenesis in mice (Marin et al., 2006) . PPAR␦ is a key regulator of skeletal muscle lipid oxidation, and, as outlined in section III, activation of PPAR␦ should have many potential beneficial effects in the context of metabolic disease. PPAR␦-mediated effects in tissues other than skeletal muscle have also highlighted the possible utility of activators of PPAR␦ for treatment of dyslipidemia and atherosclerosis (Takahashi et al., 2007; Billin, 2008; Reilly and Lee, 2008) . Considering that diabetic patients have decreased cardiac glucose utilization and an increase in myocardial fatty acid uptake and oxidation, PPAR␦ agonists might be useful therapeutic agents in treating lipotoxic cardiomyopathy.
Although genetic data link PPARD polymorphisms to enhanced glucose metabolism in skeletal muscle (Vä nttinen et al., 2005) , and clinical correlative evidence between PPAR␦ activation and improved whole-body glucose metabolism (Fritz et al., 2006; Stefan et al., 2007) , there is also evidence that PPAR␦ agonism (induced by GW610742X administration in rats), inhibits carbohydrate oxidation during contraction by blunting PDC activation (Constantin-Teodosiu et al., 2009 ). Thus, it is possible that pharmacological activation of PPAR␦ with 388 EHRENBORG AND KROOK agonist and ligands and the results obtained after physiological intervention such as training will be different. Indeed, from a skeletal muscle perspective, a key question remains whether the increased lipid oxidation will mediate long-term metabolic benefits, particularly when a sedentary lifestyle is maintained. In line with this, a recent report has proposed that obesity results in an excessive fatty acid load on mitochondria, causing accumulation of incompletely oxidized intermediates, including acylcarnitine esters, while decreasing levels of metabolites of the tricarboxylic acid cycle (Koves et al., 2008) . Mice with targeted deletion of either malonyl-CoA decarboxylase 1 (Koves et al., 2008) or PDK4 (Jeoung and Harris, 2008) are protected against diet-induced insulin resistance. In both these scenarios, skeletal muscle lipid oxidation is suppressed, and utilization of glucose is increased (Bouzakri et al., 2008; Jeoung and Harris, 2008) , which is the inverse of what is known in the response to activation of PPAR␦. The limited information available from pharmacological activation of PPAR␦ in humans, however, has indicated increased lipid oxidation and enhanced insulin sensitivity (Karpe and Ehrenborg, 2009 ). On the other hand, it remains to be seen whether the PPAR␦-mediated increase in skeletal muscle lipid oxidation would confer metabolic benefits that are sustainable in the context of a sedentary, low-energy lifestyle. The outcome of longer-term clinical trials are eagerly awaited.
B. Will Peroxisome Proliferator-Activated Receptor ␦ Agonists Be "Exercise" Pills?
With all the evidence linking activation, or total skeletal muscle content of PPAR␦, to muscle performance, it is interesting to speculate whether pharmacological activators would enhance physical performance. Indeed, many less reputable Internet pages promise enhanced muscle growth and performance by use of PPAR␦ activators. Recent evidence may actually prove that some of these claims are correct, at least in part. Administration of GW0742 to adult mice resulted in increased myofiber numbers and increased oxidative capacity (Gaudel et al., 2008) . Likewise, administration of the GW501516 to sedentary mice for 4 weeks increased skeletal muscle expression of a number of important oxidative genes (Narkar et al., 2008) . In the latter case, however, drug administration did not alter the muscle fiber type or enhance the endurance capacity of the mice. However, when GW501516 was administered to mice that were undergoing an exercise training program, then the PPAR␦ agonist increased exercise-induced improvements in endurance (Narkar et al., 2008) . If these results translate to the human situation, activation of PPAR␦ might boost the effect of exercise that is per- formed. This has implications beyond exercise performance. As discussed in section IV.C, there is emerging evidence that the ability of exercise to affect metabolic health may vary within the general population; some people may be more "exercise resistant." This opens up the possibility that pharmacological activation of PPAR␦ may boost the efficacy of exercise training in subjects that seem to be relatively unresponsive to exercise-mediated effects on metabolism. Thus, although pharmacological activation of PPAR␦ may indeed potentiate the daily training benefits induced by exercise, both for the amateur and elite athlete, it will not supersede the need to actually perform the exercise.
